Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Treakisym RI + Rituximab in B-cell Lymphomas
NCT03900377Phase 2Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bendamustine in non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by SymBio Pharmaceuticals. Primary endpoints: Adverse events at 36 weeks and Dose Limiting Toxicity at 36 weeks. Started Apr 2019; status: completed.
02
Drugs
bendamustine
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03900377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900377.